Analysts’ Upgrades for July, 11th (PRI, PRIM, PRTO, PSDO, PTGX, QTRX, RCUS, RESN, REV, RGCO)

Analysts’ upgrades for Wednesday, July 11th:

Primerica (NYSE:PRI) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Primerica, Inc. provides financial products and services. It assists its clients in meeting their needs for term life insurance, which it underwrites, and mutual funds, variable annuities and other financial products, which it distributes primarily on behalf of third parties. The Company’s mission is to serve middle income families by helping them make informed financial decisions and providing them with a strategy and means to gain financial independence. The Company’s sales representatives use its proprietary financial needs analysis, or FNA, tool and an educational approach to demonstrate how its products can assist clients to provide financial protection for their families, save for their retirement and manage their debt. The Company’s clients are generally middle income consumers. Primerica also provides an entrepreneurial business opportunity for individuals to distribute its financial products. The Company is based in Duluth, Georgia. “

Primoris Services (NASDAQ:PRIM) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Primoris Services Corporation, through various subsidiaries, operates as one of the largest specialty contractors and infrastructure companies in the United States. The Company provides a wide range of construction, fabrication, maintenance, replacement, water and wastewater, and engineering services to major public utilities, petrochemical companies, energy companies, municipalities, and other customers. It operates through three segments: East Construction Services; West Construction Services; and Engineering. Primoris Services Corporation is headquartered in Dallas, Texas. “

Proteon Therapeutics (NASDAQ:PRTO) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $3.00 price target on the stock. According to Zacks, “Proteon Therapeutics Inc. is a biopharmaceutical company. The Company is developing pharmaceuticals to address the medical needs of patients with kidney and vascular diseases. It is developing PRT-201, a recombinant human elastase, applied in a single treatment to the external surface of arteries and veins during an open surgical procedure or an endovascular intervention. Proteon Therapeutics Inc. is headquartered in Waltham, Mass. “

Presidio (NASDAQ:PSDO) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Presidio, Inc. provides information technology services. The Company offers enterprise-class solutions, including advanced networking, data analytics and center modernization, hybrid and multi-cloud, cyber risk management, and enterprise mobility as well as a broad suite of professional services, including strategy, consulting, design and implementation. It serves healthcare, education, media and entertainment, retail, manufacturing and distribution and energy and utilities sectors. Presidio, Inc. is based in New York. “

Protagonist Therapeutics (NASDAQ:PTGX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company’s initial lead product candidates consists of PTG-100 and PTG-200, which have the potential to transform the existing treatment paradigm for inflammatory bowel disease, a GI disease consisting primarily of ulcerative colitis and Crohn’s disease; PTG-300, an injectable hepcidin mimetic. Protagonist Therapeutics, Inc. is based in Milpitas, United States. “

Quanterix (NASDAQ:QTRX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Quanterix Corporation is a developer of tools in high definition diagnostics. The Company focuses on research and diagnostics for brain injuries, heart disease, cancer and other diseases with its technology. It offers Simoa consumables, which include Simoa Discs, Simoa Cuvettes, Simoa Sealing Oil, Simoa Buffers and Disposable Tips. The company services include Simoa Accelerator Lab and custom assay development services. Quanterix Corporation is based in LEXINGTON, United States. “

Arcus Biosciences (NYSE:RCUS) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company’s product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA. “

Resonant (NASDAQ:RESN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Resonant Inc. is a development-stage company. It creates filter designs for radio frequency front-ends for the mobile device industry. The Company’s product configures resonators, the building blocks of RF filters to select desired radio frequency signals and reject unwanted signals. Resonant Inc. is based in Santa Barbara, California. “

Revlon (NYSE:REV) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Revlon, Inc. conducts its business exclusively through its subsidiary, Revlon Consumer Products Corp. and its subsidiaries. They manufacture, market and sell an extensive array of cosmetics and skin care, fragrances and personal care products. Their brand names are REVLON, COLORSTAY, REVLON AGE DEFYING, ALMAY and ULTIMA II in cosmetics; MOON DROPS, ETERNA 27, ULTIMA II and JEANNE GATINEAU in skin care; CHARLIE and FIRE & ICE in fragrances; and FLEX, OUTRAGEOUS, MITCHUM, COLORSTAY, COLORSILK, JEAN NATE, PLUSBELLE, BOZZANO and COLORAMA in personal care. “

RGC Resources (NASDAQ:RGCO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “RGC Resources, Inc. has thousands of customers through its natural gas distribution companies that serve the Roanoke Valley and Bluefield, Virginia and West Virginia areas and Diversified Energy Company, which serves the Roanoke Valley, Southwestern Virginia and Southern West Virginia. The company’s stock will continue to be listed on the Nasdaq National Market, trading symbol RGCO. (PRESS RELEASE) “

RAKUTEN Inc/ADR (OTCMKTS:RKUNY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Rakuten, Inc. engages in the internet services business. Its operating segments consist of Internet Services, FinTech and Others. Internet Services segment manages e-commerce, online cash-back, travel booking, and portal and digital content sites. FinTech segment provides services over the internet related to banking and securities, credit cards, life insurance and electronic money. Others segment includes the provision of messaging and communication services and management of a Japanese professional baseball team. Rakuten, Inc. is headquartered in Tokyo, Japan. “

Red Lion Hotels (NYSE:RLH) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Red Lion Hotels Corporation, established in 1959, is an international hospitality company primarily engaged in the franchising, management and ownership of upscale, midscale and economy hotels under the Hotel RL, Red Lion Hotels, Red Lion Inn & Suites, GuestHouse, Settle Inn, Vantage Hotels, Americas Best Value Inn, Canadas Best Value Inn, Lexington by Vantage, America’s Best Inns & Suites, Country Hearth Inns, Jameson Inn, Signature Inn and 3 Palms Hotels & Resorts brands. The company also owns and operates an entertainment and event ticket distribution business under the brand name TicketsWest. “

Rockwell Medical (NASDAQ:RMTI) was upgraded by analysts at Zacks Investment Research from a sell rating to a buy rating. Zacks Investment Research currently has $4.75 target price on the stock. According to Zacks, “Rockwell Medical Technologies, Inc. manufactures hemodialysis concentrates and dialysis kits, and sells, distributes and delivers such concentrates and dialysis kits, as well as other ancillary hemodialysis products, to hemodialysis providers in the United States. Hemodialysis is a process which is able to duplicate kidney function in patients whose kidneys have failed to function properly. “

RingCentral (NYSE:RNG) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $83.00 price target on the stock. According to Zacks, “RingCentral, Inc. provides solutions for business communications primarily in the United States. The Company’s products include RingCentral Office, RingCentral Mobile and RingCentral Fax. It provides solutions such as auto-receptionist, flexible extension structure, multiple voicemail boxes, smart call routing, business answering rules, extension dialing, call transfers and elegant integration with Smartphones. RingCentral, Inc. is headquartered in San Mateo, California. “

Receive News & Ratings for Primerica Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Primerica Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Original Source